Role of epigenetics factor (miRNA) in diagnose and treatment of depression

Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 341

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NGCMED10_098

تاریخ نمایه سازی: 16 تیر 1397

Abstract:

Depression is a potentially debilitating mental disorder and a major public health concern which affectingapproximately 300 millions of people worldwide. Despite many researches, the molecular mechanisms about theetiopathology of depression are not obvious. Today, investigation on the epigenetic factor present interesting datain the molecular pathophysiology of depression contributing to the diagnosis of the disorder. miRNAs, DNAmethylation, histone modification and mRNAs are among factors of epigenetic mechanism research. miRNAsare small noncoding RNA molecules that regulate gene expression and modulate cellular events. They haveknown as key protagonists in numerous physiopathological conditions, including CNS function, cancer and otherdiseases. miRNAs as a novel regulatory molecule affecting drug metabolism and drug targets play an importantrole in pharmacogenomic studies and are sensitive biomarkers under toxic conditions in toxicogenomics.Exposure to xenobiotics, stress or any change in organism’s normal condition, resulted in altered expression ofgenome, which affects mRNA transcription and protein translation and consequent adverse biological effects. Inother words, different toxicants, drugs or diseases may lead to exchange in specific expression profile ofmicroRNAs. Furthermore, several miRNAs have been found that be altered in animal models and patients withdepression disorder. In the treatment, recent evidence suggests that the use of antidepressants can effect on theexpression of related genes, especially on some miRNAs. For instance, expression of miR-16 as target ofserotonin transporter (SERT) increased in depression. In the following, SSRIs as selective depression therapy canreduce its expression.

Authors

Mahnaz Ahmadinanesh

Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Mohammad Reza Abbaszadegan

Division of Human Genetics, Immunology Research Center, Bu-Ali Research Institute Mashhad University of Medical Sciences,Mashhad, Iran